Ecole Polytechnique Federale De Lausanne

The University of Texas System

Eidgenossische Technische Hochschule Zurich

Unversität Zürich

Focal, Inc.

California Institute of Technology

The University of Chicago

Other

Life Medical Sciences, Inc.

University of California

The Ohio State University

Genzyme Corporation

University of Miami

Imperial College Innovations Limited

Infimed, Inc.

Jeffrey Alan Hubbell

Amarpreet S Sawhney

Chandrashekhar Prabhakar Pathak

Neil P Desai

Donald Leo Elbert

Karen Y Dane

Stephan Kontos

David Scott Wilson

Jennifer L Hill-West

Stephen Jack Herman

Jason Schense

Stephen C Rowe

Jennifer L Hill

Arthur J Coury

George E Selecman

Syed F Hossainy

Vae E Sun

Frederick F Ahari

Ronald Schoenmakers

Stéphane Kontos

Michael F Lang

Syed F A Hossainy

Mark T Kieras

Patrick K Campbell

Peter K Jarrett

Laurence A Roth

Alice Tomei

Kevin M Berrigan

Diana Velluto

Melody Swartz

Sanghamitra Chowdhury

Kristen Marie Lorentz

Donald L Elbert

Natalie D Winblade

David A Melanson

Luis Z Avila

Paul D Drumheller

Shikha P Barman

Jane P Bearinger

Stephen D Goodrich

Marcus Textor

Ronald S Rudowsky

Shelly E Sakiyama-Elbert

Shuning Gai

Chandrashekar P Pathak

Conlin P O'Neil

Nicola Tirelli

Melody A Swartz

Shelly E Sakiyama

André Van Der Vlies

Daniel M Schwartz

Eyal S Ron

Dean M Pichon

Curtis B Herbert

Bradley C Poff

Douglas J Weaver

David J Nedder

Jun Ishihara

Ako Ishihara

Alessandro Napoli

Cathryn R Nagler

Paul Latta

Catherine Plunkett

Sai T Reddy

D Scott Wilson

Ruyi Wang

Marc A Levine

Anna Jen

Randall C Dunn

Matthias Lütolf

James Brandon Dixon

Demetri Psaltis

Kenneth J Michlitsch

John C Spiridigliozzi

Julia A Kornfield

Nicholas S Bodor

Thomas Bromander

Xiaojie Yu

Camillo D Ricordi

Hanne Bentz

Steven Paul Schwendeman

Gaozhong Zhu

Tatiana Segura

C Michael Philbrook

Luca Inverardi

Christopher A Fraker

Nicholas David Spencer

Richard L Franklin

Matthias Lutolf

Antonello Pileggi

Ye Pu

Norma Sue Kenyon

Peter Buchwald

Rolf Hofer

Laurence Ruiz-Taylor

Fabio Grassi

Jichao Kang

Thomas S Bromander

Douglas J K Weaver

Provided herein are polymer materials that find use in, for example, delivery of short-chain fatty acids. In particular, polymers are provided that form stable nanoscale structures and release their payload, for example, by cleavage of a covalent bond (e.g., via hydrolysis or enzymatic cleavage). The polymers are useful, for example, for delivery of payloads (e.g., SCFAs) to the intestine for applications in health and treatment of disease, and have broad applicability in diseases linked to changes in the human microbiota including inflammatory, autoimmune, allergic, metabolic, and central nervous system diseases, among others.

Polymer materials for delivery of short-chain fatty acids to the intestine for applications in human health and treatment of disease

Peptides that specifically bind erythrocytes are described. These are provided as peptidic ligands having sequences that specifically bind, or as antibodies or fragments thereof that provide specific binding, to erythrocytes. The peptides may be prepared as molecular fusions with therapeutic agents, tolerizing antigens, or targeting peptides. Immunotolerance may be created by use of the fusions and choice of an antigen on a substance for which tolerance is desired.

Erythrocyte-binding therapeutics

Peptides that specifically bind erythrocytes are described. These are provided as peptidic ligands having sequences that specifically bind, or as antibodies or fragments thereof that provide specific binding, to erythrocytes. The peptides may be prepared as molecular fusions with therapeutic agents, tolerizing antigens, or targeting peptides. Immunotolerance may be created by use of the fusions and choice of an antigen on a substance for which tolerance is desired. Fusions with targeting peptides direct the fusions to the target, for instance a tumor, where the erythrocyte-binding ligands reduce or entirely eliminate blood flow to the tumor by recruiting erythrocytes to the target.

Several embodiments of the present disclosure relate to therapeutic compositions configured to target the liver of a subject and that are useful in the treatment or prevention of one or more of transplant rejection, autoimmune disease, food allergy, and immune response against a therapeutic agent. In several embodiments, the compositions are configured to target the liver and deliver antigens to which tolerance is desired. In several embodiments, the compositions are configured for clearance of a circulating protein or peptide or antibody associated with one or more of the above-mentioned maladies. Methods and uses of the compositions for induction of immune tolerance are also disclosed herein.

Glycotargeting therapeutics

Several embodiments of the present disclosure relate to glycotargeting therapeutics that are useful in the treatment of transplant rejection, autoimmune disease, food allergy, and immune response against a therapeutic agent. In several embodiments, the compositions are configured to target the liver and deliver antigens to which tolerance is desired. Methods and uses of the compositions for induction of immune tolerance are also disclosed herein.

The methods and compositions described herein address the need in the art by providing peptides and polypeptides comprising a growth factor binding domain. In some embodiments, the peptides have an amino acid sequence that is at least 80% identical to one of SEQ ID NOS:1-7, 13-15, 49-50, or 66-70, or a fragment thereof; wherein the peptide is less than 300 amino acids in length.

Methods and compositions for the treatment of wounds

Glycotargeting therapeutics are useful in the treatment of transplant rejection, autoimmune disease, food allergy, and immune response against a therapeutic agent.

Hydrodynamic methods for conformally coating non-uniform size cells and cell clusters for implantation, thus preventing immune rejection or inflammation or autoimmune destruction while preserving cell functionality. A method for conformally coating cells and c clusters with hydrogels that are biocompatible, mechanically and chemically stable and porous, with an appropriate pore cut-off size. The methods of the invention are advantageously reproducible and result in a relatively high yield of coated versus non-coated cell clusters, without compromising cell functionality. Conformal coating devices configured to perform the methods of the invention, methods of optimally utilizing said devices and purifying the coated islets, and coated biomaterials made by said methods.

Conformal coating of cells for immunoisolation

The methods and compositions described herein address the need in the art by providing compositions and methods for a therapy with an antibody that is specifically targeted to and/or retained intra- or peri-tumorally, limiting systemic exposure and reducing side-effects. Accordingly, aspects of the disclosure relate to a composition comprising an immunotherapeutic antibody operatively linked to an extracellular matrix (ECM)-affinity peptide. An ECM-affinity peptide is one that has affinity for an extracellular matrix protein.

Methods of treating cancer with placenta growth factor peptide linked to immunotherapeutic antibodies

Monomers and copolymers are provided that both target antigen presenting cells (APCs) and activate toll-like receptor (TLR) on the APCs. In some embodiments, compositions and methods involve a polymer that targets the mannose receptor on APCs, in addition to activating a TLR. These can then be conjugated to protein antigens to efficiently target antigens to DCs and simultaneously induce the up-regulation of co-stimulatory molecules that are essential for effective T cell activation. This copolymer is a more efficient activator of DCs, as measured by the surface expression of co-stimulatory molecules and the release of proinflammatory cytokines, than the monomeric form the TLR agonist used in the polymer formulation. Aspects of the disclosure relate to novel compounds, methods, and compositions for treating diseases using the compounds, copolymers, and compositions described herein.

Polymer conjugate vaccines

The invention relates to methods for producing a polymeric scaffold for use in tissue engineering applications or soft tissue surgery, as well as to the produced scaffolds and an associated kit. The method features a first fast drying step of applying a mechanical compression on a polymeric gel layer and a second slow drying step of the gel up to reach a polymer mass fraction of at least 60% w/w in the final scaffold. The method allows the production of scaffolds with high regeneration and healing properties of a grafted tissue via host cell invasion and colonization, and a good suturability. These goals are achieved through the formation within the scaffold of a non-uniform architecture creating softer and stiffer areas, which is maintained even upon re-swelling of the scaffold upon hydration of the final dried product.

Non-uniformly stiff polymeric scaffolds and methods for producing thereof

Several embodiments provided in the present disclosure relate to compositions that carry an antigen to which tolerance is desired, the antigen being coupled, bound, or otherwise joined to a targeting moiety, the targeting moiety configured to direct the composition to the liver of a subject. In several embodiments, the antigen in coupled to the targeting moiety by way of a polymeric linker. In several embodiments, the polymeric linker is configured to liberate the antigen in vivo. Methods of using the compositions to reduce and/or prevent unwanted immune responses against an antigen of interest are also provided.

Compositions and methods for inducing immune tolerance

Antigen-specific tolerance and compositions for induction of same

Growing community of inventors

Zumikon, Switzerland

Jeffrey Alan Hubbell